Table II.
Baseline disease characteristics of patients.
| Subject characteristics | Survivors (n=51) | Non-survivors (n=33) | P-value |
|---|---|---|---|
| AAA initial diameter (cm) | 5.3±0.8 | 6.4±1.2 | 0.13 |
| Length of AAA (cm) | 7.3±2.3 | 8.5±2.0 | 0.62 |
| Left iliac involvement | 7 (13.7) | 8 (24.2) | 0.25 |
| Right iliac involvement | 8 (15.7) | 10 (30.3) | 0.17 |
| Renal artery involvement | 2 (3.9) | 3 (9.1) | 0.38 |
| Medication history | |||
| β-blocker | 40 (78.4) | 27 (81.8) | 0.79 |
| Statin | 46 (90.2) | 29 (87.9) | 0.73 |
| ACE inhibitor/ARB | 29 (56.9) | 21 (63.6) | 0.65 |
| Daily aspirin | 45 (88.2) | 30 (90.9) | <0.99 |
| Anticoagulant | 14 (27.5) | 10 (30.3) | 0.81 |
Values are expressed as the mean ± standard deviation for continuous variables (comparisons performed with Student t-test) and as n (%) for categorical variables (comparisons performed with χ2 test). AAA, abdominal aortic aneurysm; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.